Foreign Price Controls on Medicines Are a Step in the Wrong Direction
- Most-Favored Nation (MFN) pricing threatens the U.S.'s leadership in biopharmaceutical innovation by disincentivizing investment in research and development, which is critical for discovering new treatments and cures.
- Importing foreign price controls into the U.S. healthcare system undermines the innovation ecosystem, delaying access to life-saving medicines and jeopardizing future medical breakthroughs.
- Instead of adopting harmful price control policies, the U.S. should focus on market-driven solutions that lower costs while preserving the incentives that drive medical innovation and protect patient access.
